Sermorelin + CJC-1295 Stack: Complete Protocol, Dosing, and Clinical Evidence

What Is the Sermorelin + CJC-1295 Stack?

Stacking sermorelin with CJC-1295 means administering two structurally related GHRH analogs together so that their pharmacokinetic profiles complement each other. Sermorelin, a 29-amino-acid fragment of endogenous GHRH, triggers a sharp, physiologic GH pulse within minutes. CJC-1295 extends that pulse by occupying GHRH receptors for a longer window, increasing total GH area-under-the-curve without fully blunting the natural pulsatility that keeps IGF-1 receptors sensitive.

Why Not Just Use One?

Sermorelin alone produces GH peaks that mirror natural secretion but fade quickly. CJC-1295 alone, particularly the formulation that carries the Drug Affinity Complex (DAC), binds to albumin and maintains elevated GH stimulation for nearly a week. That sustained stimulation is pharmacologically distinct from physiologic GHRH, and some practitioners consider it less desirable than short, distinct pulses for long-term use. Combining short-acting sermorelin with the non-DAC form of CJC-1295 tries to capture amplitude from sermorelin and duration from CJC-1295 (no DAC) while preserving pulsatility.

Evidence Base and Its Limits

Direct RCT data on this exact combination does not exist as of early 2025. The rationale is built from three layers of evidence:

1. Individual peptide pharmacology studies
2. Animal growth-hormone secretion models
3. Practitioner-reported outcomes from compounding pharmacy-based protocols

That evidence hierarchy is weaker than an RCT. Readers should treat the dosing guidance below as a starting framework, not a validated clinical protocol.

How Sermorelin Works: Mechanism and Pharmacokinetics

Sermorelin acetate is a synthetic analog of endogenous GHRH(1-29)NH2. It binds the pituitary GHRH receptor and triggers GH release within minutes. The FDA approved sermorelin (Geref) for pediatric growth hormone deficiency in 1997, and the label was voluntarily withdrawn from the U.S. Market in 2008 for commercial, not safety, reasons [1].

Receptor Binding and GH Release

GHRH binds a G-protein-coupled receptor on anterior pituitary somatotroph cells, activating adenylyl cyclase and raising intracellular cAMP. That cascade stimulates both GH synthesis and secretion. Sermorelin replicates this mechanism using only the first 29 amino acids of the 44-amino-acid native hormone, which is the minimum sequence needed for full receptor activation [2].

Rapid Clearance

Plasma half-life for sermorelin is approximately 10 to 12 minutes. A peak in serum GH typically appears 20 to 40 minutes after subcutaneous injection and returns to baseline within 2 to 3 hours. That rapid clearance preserves the pulsatile pattern of GH release, a feature that matters because GH receptor downregulation is partly driven by continuous (rather than pulsatile) stimulation [3].

Safety Data from the Geref NDA Period

In pediatric growth hormone deficiency trials supporting the original Geref NDA, sermorelin produced meaningful increases in growth velocity with a side-effect profile limited largely to injection-site redness, flushing, and, rarely, transient facial flushing at higher doses. Antibody formation occurred in fewer than 1% of treated children and was not associated with clinical consequences [1].

How CJC-1295 Works: Mechanism and Pharmacokinetics

CJC-1295 is a synthetic GHRH analog modified to resist enzymatic degradation. Two commercially relevant forms exist: CJC-1295 without DAC (also called modified GRF 1-29 or Mod GRF 1-29) and CJC-1295 with DAC.

CJC-1295 Without DAC

Mod GRF 1-29 carries four amino acid substitutions relative to native GHRH(1-29) that block dipeptidyl peptidase IV (DPP-IV) cleavage and other proteolytic sites. The result is a half-life of roughly 30 minutes to 2 hours, substantially longer than sermorelin but still physiologically pulsatile. Published pharmacokinetic work by Ionescu and Frohman demonstrated that these substitutions increase receptor-binding duration without creating the near-continuous stimulation seen with the DAC formulation [4].

CJC-1295 With DAC

Adding the DAC moiety enables covalent binding to circulating albumin, extending half-life to 6 to 8 days. A phase-II trial (N=65) published by Teichman et al. Showed that a single injection of CJC-1295 with DAC at 60 mcg/kg produced mean GH increases of 2- to 10-fold and IGF-1 increases of 1.3- to 1.5-fold that persisted for 6 days [5]. That same study reported no serious adverse events, but the persistent elevation of GH stimulation is a pharmacologic profile that differs from anything the pituitary generates naturally.

Which Form Belongs in This Stack?

Most practitioners pair sermorelin with the no-DAC form (Mod GRF 1-29) rather than the DAC form. The reasoning: sermorelin + CJC-1295 no-DAC allows each co-injected dose to produce a defined, syncopated GH pulse that clears between doses. Using the DAC form stacks a week-long stimulus on top of every daily sermorelin injection, flattening pulsatility and potentially suppressing somatostatin rebound, which is one of the regulators that keeps GH output healthy.

Dosing Protocol: Sermorelin + CJC-1295 (No DAC)

The following framework reflects synthesis of published GHRH pharmacokinetics, the Teichman et al. Phase-II dose-finding data, and practitioner-reported protocols used at compounding-pharmacy-partnered telehealth practices. No RCT has tested this exact combination or these exact doses. IGF-1 monitoring is required before and during any protocol.

Starting Doses

| Compound | Starting Dose | Titrated Dose | Route | |---|---|---|---| | Sermorelin | 200 mcg | 300 to 500 mcg | Subcutaneous | | CJC-1295 (no DAC) | 100 mcg | 150 to 200 mcg | Subcutaneous |

Both peptides are co-injected in the same syringe because they are compatible in solution and require the same subcutaneous injection technique. The abdomen, lateral thigh, or lateral deltoid are acceptable sites.

Injection Timing

Inject once daily, 30 to 60 minutes after the last meal of the evening, at least 2 hours before bed. Fasting state matters because elevated insulin blunts GH secretion by raising somatostatin tone. A 2020 review in the Journal of Clinical Endocrinology and Metabolism confirmed that post-meal hyperinsulinemia suppresses GH pulse amplitude by roughly 80% within 2 hours of a carbohydrate-rich meal [6].

Bed-time injection aligns with the dominant physiologic GH pulse, which occurs during slow-wave sleep. Endogenous GHRH rises sharply in the first hours of sleep, so pharmacologic support at that time theoretically amplifies a natural secretory event rather than creating an ectopic one.

Titration Schedule

• Weeks 1 to 2: Sermorelin 200 mcg + CJC-1295 no-DAC 100 mcg nightly
• Weeks 3 to 4: Increase sermorelin to 300 mcg if IGF-1 response is subtherapeutic (below the mid-range for age and sex) and no adverse effects present
• Week 5 onward: Titrate sermorelin up to 500 mcg based on serum IGF-1 and symptom response

Do not exceed 500 mcg sermorelin or 200 mcg CJC-1295 (no DAC) per injection without a physician review of IGF-1 and clinical response data.

Cycle Length and Off-Periods

Run the stack for 3 to 6 months continuously, then take a 4 to 8 week break before resuming. Long uninterrupted cycles may theoretically reduce pituitary GHRH receptor density through receptor downregulation, though published duration-response data specifically for sermorelin in adults is limited. The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency in adults does not endorse any specific secretagogue cycling schedule, but endorses periodic reassessment of IGF-1 to avoid supraphysiologic exposure [7].

Monitoring: Labs and Clinical Endpoints

Running either peptide without laboratory monitoring converts a pharmacologic intervention into guesswork. The minimum lab panel before and during this stack is:

Baseline Labs (Before Starting)

• Serum IGF-1 (age- and sex-referenced)
• Fasting glucose and HbA1c (GH can worsen insulin sensitivity at supraphysiologic levels)
• Comprehensive metabolic panel
• Fasting lipid panel
• Morning cortisol (to rule out untreated HPA axis disorders)
• For men over 40: PSA and total testosterone
• For women: FSH, LH, estradiol (pre- or post-menopausal staging affects IGF-1 reference ranges)

On-Therapy Monitoring Schedule

Check serum IGF-1 at 6 to 8 weeks after starting and again at 3 to 4 months. The therapeutic target for most adults is an IGF-1 value in the upper half of the age- and sex-specific reference range, typically 150 to 350 ng/mL depending on the lab and age bracket. An IGF-1 reading above the upper limit of the reference range at any point is a signal to reduce dose or pause the stack.

A 2001 meta-analysis by Shalet et al. Found that supraphysiologic IGF-1 elevation, defined as consistently above the age-adjusted 97.5th percentile, was associated with increased fasting glucose and worsening insulin sensitivity in growth hormone-deficient adults [8]. That finding applied to exogenous recombinant hGH, but the principle extends to secretagogue stacks that drive IGF-1 into the same range.

Side Effects and Risk Profile

Neither peptide is free of adverse effects. The risk profile of the stack combines the individual profiles of each compound.

Common and Expected Effects

• Injection-site reactions (redness, mild swelling): reported in 10 to 20% of users in sermorelin NDA data [1]
• Flushing or warmth in the face within 30 minutes of injection: related to rapid vasodilation from GH release
• Transient water retention (edema in hands and feet): a class effect of elevated GH, usually resolves within 2 to 4 weeks as the body adapts
• Increased appetite: GH raises ghrelin sensitivity, and some patients report noticeable hunger increases within the first 2 to 4 weeks

Potentially Serious Effects

• Glucose dysregulation: GH is counter-regulatory to insulin. Patients with pre-diabetes or metabolic syndrome need more frequent fasting glucose checks (every 4 weeks for the first 3 months). The American Diabetes Association notes that GH excess is a recognized secondary cause of diabetes [9].
• Carpal tunnel syndrome: Fluid retention around the median nerve. GH-related carpal tunnel is dose-dependent and typically resolves with dose reduction.
• Pituitary suppression concern (theoretical): Because both peptides stimulate the same receptor, sustained co-administration could theoretically down-regulate pituitary GHRH receptor expression. No human data quantifies this risk for the specific combination.

Who Should Not Use This Stack

Absolute contraindications include active malignancy (IGF-1 is mitogenic and could promote tumor growth), untreated hypothyroidism (thyroid hormone is required for normal GH axis function; treating hypothyroidism first often restores GH pulsatility without peptides), pregnancy, and active proliferative diabetic retinopathy.

Sermorelin + CJC-1295 Versus Other GH Secretagogue Stacks

Clinicians and patients often compare this stack to sermorelin + ipamorelin, sermorelin + GHRP-6, or CJC-1295 (no DAC) + ipamorelin. The comparison points are below.

Versus Sermorelin + Ipamorelin

Ipamorelin is a selective GHRP (growth hormone-releasing peptide), not a GHRH analog. Combining a GHRH analog with a GHRP exploits two distinct receptor pathways and typically produces a larger GH pulse than combining two GHRH analogs. The GHRH + GHRP approach has more published mechanistic support. Bowers et al. Demonstrated supra-additive GH release when GHRH and GHRP-6 were co-administered in healthy adults [10]. The sermorelin + CJC-1295 stack, using two GHRH analogs, likely produces additive rather than supra-additive GH release because both peptides compete for the same receptor pool.

Versus CJC-1295 (No DAC) + Ipamorelin Alone

The CJC-1295 (no DAC) + ipamorelin combination is arguably more studied and more commonly prescribed in compounding pharmacy practice than sermorelin + CJC-1295. Adding sermorelin to an existing CJC-1295 (no DAC) regimen saturates GHRH receptors more completely during the injection window, which may increase pulse amplitude modestly, but no published trial has measured that incremental gain.

Regulatory and Legal Status

Sermorelin acetate was FDA-approved for pediatric use (Geref injectable, Serono Laboratories) but voluntarily withdrawn in 2008. It has no current FDA-approved indication. CJC-1295 has never received FDA approval for any indication.

Both peptides are permitted to be compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act when a licensed physician provides a patient-specific prescription to a state-licensed compounding pharmacy. The FDA has periodically placed specific peptides on its list of "difficult to compound" drugs or Category 1/2 nominee lists under the DQSA. As of the most recent FDA guidance update, sermorelin remains compoundable under 503A; practitioners should verify the current status at the time of prescribing because this regulatory position has shifted multiple times [11].

Neither peptide is approved for use in competitive athletes. WADA includes all GHRH analogs and GH secretagogues on the Prohibited List under Section S2 (Peptide Hormones, Growth Factors, and Related Substances) [12].

Practical Protocol Summary

The evidence-based practitioner approach to this stack follows a sequence. Start with a complete baseline lab panel and a clinical history that rules out contraindications. Prescribe sermorelin 200 mcg + CJC-1295 (no DAC) 100 mcg nightly, co-injected subcutaneously. Recheck serum IGF-1 at 6 to 8 weeks. If IGF-1 is in the lower half of the reference range and the patient tolerates the protocol, titrate sermorelin to 300 to 500 mcg. Run 3 to 6 months continuously, then reassess whether to continue, pause for 4 to 8 weeks, or transition to a different GH-secretagogue strategy.

The Endocrine Society's adult GH deficiency guideline states: "The goal of GH replacement is to normalize serum IGF-1 concentrations for age and sex and to improve the clinical features of GHD without causing adverse effects from GH excess" [7]. That principle applies equally when using secretagogues rather than exogenous GH.

The one measured outcome that matters most at follow-up is serum IGF-1. Target the upper half of the age-and-sex-referenced range, typically 150 to 350 ng/mL for adults aged 30 to 60.